Correction to BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: Results of the ORHEO observational study [BMC Cancer, 14, (2014), 503], doi: 10.1186/1471-2407-14-503;BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: Results of the ORHEO observational study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Michallet, Mauricette ^a   Luporsi, Elisabeth ^b   Soubeyran, Pierre ^c   Amar, Nadia A ^d   Boulanger, Vincent ^e   Carreiro, Miguel ^f   Dourthe, Louis Marie ^g   Labourey, Jean Luc ^e,h   Lepille, Daniel ⁱ   Maloisel, Frédéric ^g   Mouysset, Jean Loup ^j   Nahon, Sophie ^k   Narciso, Bérengère ^l   Nouyrigat, Pierre ^m   Radji, Raouf ⁿ   Sakek, Nacéra ^o   Albrand, Hélène ^p  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c INSTITUT BERGONIÉ   (France)

^d CENTRE HOSPITALIER DE TROYES   (France)

^e Centre Hospitalier de Carcassonne   (France)

^f Centre Hospitalier de Montauban   (France)

^g Clinique Sainte Anne   (France)

^h polyclinique Montréal ELSAN   (France)

ⁱ CLINIQUE PASTEUR   (France)

^j Clinique Rambot Provencale   (France)

^k Centre hospitalier d'Aix en Provence   (France)

^l UNIVERSITY HOSPITAL OF TOURS   (France)

^m Clinique du Cap d'Or   (France)

ⁿ Centre Frédéric JOLLIOT   (France)

^o Centre Hospitalier Montbéliard   (France)

^p Laboratoire HOSPIRA France   (France)

more..

Author keywords

Anaemia; Biosimilar; Chemotherapy; Epoetin; ESA

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; BIOSIMILAR AGENT; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

AGED; ARTICLE; BLEEDING; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; ELEVATED BLOOD PRESSURE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; LONGITUDINAL STUDY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; OBSERVATIONAL STUDY; SIDE EFFECT; SOLID TUMOR; THROMBOEMBOLISM; TREATMENT INDICATION; ADULT; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; MULTICENTER STUDY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANEMIA; CHEMICALLY INDUCED; COMPLICATION; FRANCE; HEMATOLOGIC NEOPLASMS; MIDDLE AGED;

ADULT; AGED; ANEMIA; BIOSIMILAR PHARMACEUTICALS; ERYTHROPOIETIN; FEMALE; FRANCE; HEMATOLOGIC NEOPLASMS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 84905369715     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-720     Document Type: Erratum

References (27)

1. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004, 40:2293-2306.
2. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004, 15:979-986.
3. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001, 91:2214-2221.
4. Aapro MS. Anemia management with erythropoiesis-stimulating agents: a risk-benefit update. Oncologist 2008, 13(Suppl 3):1-3.
5. Ludwig H. Anemia of hematologic malignancies: what are the treatment options?. Semin Oncol 2002, 29(Suppl 8):45-54.
6. Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pat Lab Med 2007, 131:702-707.
7. Bernard AC, Davenport DL, Chang PK, Vaughan TB, Zwischenberger JB. Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J Am Coll Surg 2009, 208:931-937.
8. Koch CG, Li L, Duncan AI, Mihaljevic T, Loop FD, Starr NJ, Blackstone EH. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg 2006, 81:1650-1657.
9. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008, 3:200-207.
10. Topf JM. CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008, 9:839-849.
11. Wauters I, Vansteenkiste J. Darbepoetin alfa in the treatment of chemotherapy-induced anaemia. Expert Opin Biol Ther 2009, 9:221-230.
12. Bohlius J, Tonia T, Schwarzer G. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. Acta Haematol 2011, 125:55-67.
13. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373:1532-1542.
14. Brinks V, Hawe A, Basmeleh AH, Joachin-Rodriguez L, Haselberg R, Somsen GW, Jiskoot W, Schellekens H. Quality of original and biosimilar epoetin products. Pharm Res 2011, 28:386-393.
15. European Generic Medicines Association Biosimilars Handbook 2011, London: Sage Publications Ltd, 2, European Generic Medicines Association.
16. CHMP Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf, CHMP.
17. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Nat Cancer Inst 1999, 91:1616-1634.
18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
19. Aapro M, Cornes P, Sun D, Abraham I. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol 2012, 4:95-105.
20. Tzekova V, Mihaylov G, Elezovic I, Koytchev R. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia. Curr Med Res Opin 2009, 25:1689-1697.
21. Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001, 113:172-179.
22. Zonder JA. Thrombotic complications of myeloma therapy. Hematology Am Soc Hematol Educ Program 2006, 348-355.
23. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol 2006, 77:378-386.
24. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadié M, Simonetti A, Lutz JM, Berrino F. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010, 116:3724-3734.
25. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
26. Schrijvers D, De Samblanx H, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010, 21(Suppl. 5):v244-v247.
27. Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM. NCCN Biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw 2011, 9(Suppl. 4):S1-S22.